A twenty-six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of transition to Toujeo compared to standard of care insulin, in basal insulin treated patients with uncontrolled type 2 diabetes mellitus, with six month extension.
Phase of Trial: Phase IV
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REGAIN CONTROL
- Sponsors Sanofi
- 18 Nov 2017 This trial has been completed in Finland (2017-10-20).
- 31 Oct 2017 Status changed from active, no longer recruiting to completed.
- 28 Oct 2017 This trial has been completed in Spain.